CRISPR-CAS9-SGRNA COMPLEX AND METHODS FOR CLONING APPLICATIONS

Mustapha Aouida; Dindial Ramotar; Maryam Saifaldeen; Dana Essa Al Ansari

CRISPR-CAS9-SGRNA COMPLEX AND METHODS FOR CLONING APPLICATIONS

Mustapha Aouida (Inventor)
, Dindial Ramotar (Inventor)
, Maryam Saifaldeen (Inventor)
, Dana Essa Al Ansari (Inventor)

Qatar Foundation for Education, Science, and Community Development

Research output: Patent

Abstract

The creation of the nuclease-dead Cas protein (dCas9) offers a new platform for a plethora of new discoveries. The presently disclosed dCas9 and single-guide RNA, preassembled to form ribonucleoprotein dCas9-sgRNA (referred to as dRNPC), is capable of specifically and reversibly blocking the activity of DNA cleavage by restriction enzymes. The inhibition of restriction enzyme activities occurs when the sgRNA or the PAM sequence overlaps the recognition or the cleavage site of the DNA. The multiple dRNPC can simultaneously inhibit more than one restriction enzyme site. The disclosed method can be used to ligate inserts into vectors, and vice versa, whereby selective restriction enzyme sites are temporarily sheltered to allow the desired cloning.

Original language	English
Patent number	WO2022093056
IPC	C12N 15/ 90 A I
Priority date	26/10/20
Publication status	Published - 5 May 2022

Cite this

@misc{99ad5b5e3ec34b24bfae36b9a07f129a,

title = "CRISPR-CAS9-SGRNA COMPLEX AND METHODS FOR CLONING APPLICATIONS",

abstract = "The creation of the nuclease-dead Cas protein (dCas9) offers a new platform for a plethora of new discoveries. The presently disclosed dCas9 and single-guide RNA, preassembled to form ribonucleoprotein dCas9-sgRNA (referred to as dRNPC), is capable of specifically and reversibly blocking the activity of DNA cleavage by restriction enzymes. The inhibition of restriction enzyme activities occurs when the sgRNA or the PAM sequence overlaps the recognition or the cleavage site of the DNA. The multiple dRNPC can simultaneously inhibit more than one restriction enzyme site. The disclosed method can be used to ligate inserts into vectors, and vice versa, whereby selective restriction enzyme sites are temporarily sheltered to allow the desired cloning.",

author = "Mustapha Aouida and Dindial Ramotar and Maryam Saifaldeen and \{Al Ansari\}, \{Dana Essa\}",

year = "2022",

month = may,

day = "5",

language = "English",

type = "Patent",

note = "WO2022093056; C12N 15/ 90 A I",

}

TY - PAT

T1 - CRISPR-CAS9-SGRNA COMPLEX AND METHODS FOR CLONING APPLICATIONS

AU - Aouida, Mustapha

AU - Ramotar, Dindial

AU - Saifaldeen, Maryam

AU - Al Ansari, Dana Essa

PY - 2022/5/5

Y1 - 2022/5/5

N2 - The creation of the nuclease-dead Cas protein (dCas9) offers a new platform for a plethora of new discoveries. The presently disclosed dCas9 and single-guide RNA, preassembled to form ribonucleoprotein dCas9-sgRNA (referred to as dRNPC), is capable of specifically and reversibly blocking the activity of DNA cleavage by restriction enzymes. The inhibition of restriction enzyme activities occurs when the sgRNA or the PAM sequence overlaps the recognition or the cleavage site of the DNA. The multiple dRNPC can simultaneously inhibit more than one restriction enzyme site. The disclosed method can be used to ligate inserts into vectors, and vice versa, whereby selective restriction enzyme sites are temporarily sheltered to allow the desired cloning.

AB - The creation of the nuclease-dead Cas protein (dCas9) offers a new platform for a plethora of new discoveries. The presently disclosed dCas9 and single-guide RNA, preassembled to form ribonucleoprotein dCas9-sgRNA (referred to as dRNPC), is capable of specifically and reversibly blocking the activity of DNA cleavage by restriction enzymes. The inhibition of restriction enzyme activities occurs when the sgRNA or the PAM sequence overlaps the recognition or the cleavage site of the DNA. The multiple dRNPC can simultaneously inhibit more than one restriction enzyme site. The disclosed method can be used to ligate inserts into vectors, and vice versa, whereby selective restriction enzyme sites are temporarily sheltered to allow the desired cloning.

M3 - Patent

M1 - WO2022093056

ER -

CRISPR-CAS9-SGRNA COMPLEX AND METHODS FOR CLONING APPLICATIONS

Abstract

Fingerprint

Cite this